NCT00936065

Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis

A Multicenter, Randomized, Open Pilot Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly Followed Etanercept 25mg Twice Weekly, the Combination of Etanercept 25 mg Twice Weekly and Acitretin and Acitretin Alone in Patients With Moderate to Severe Psoriasis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To compare the efficacy of ETN 50mg twice weekly for 12 weeks followed by reduction to a maintenance dose of 25mg twice weekly at week 24 with that of combination of ETN 25 mg Twice Weekly plus Acitretin 10mg BID at week 24 in subjects with moderate to severe psoriasis.

Conditions

• Moderate to Severe Psoriasis

Interventions

Type	Name	Description
DRUG	Etanercept	Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
DRUG	Etanercept + Acitretin	Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
DRUG	Acitretin	Acitretin at a dose of 10mg BID for 24 weeks

Timeline

• Start date: 2009-07-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2009-07-09
• Last updated: 2012-04-09
• Results posted: 2012-04-09

Locations

10 sites across 1 country: South Korea